Glivec: The patently David vs Goliath battle

Celebrating 5 years of the victory for affordable generic Imatinib

Read More

How critics say drug companies play “games” to stave off generic competitors

Lawmakers are considering a bill to address what President Trump called a top priority in his State of the Union speech: lowering prescription drug prices. Critics say some drug companies who want to hold onto their exclusive sales of a brand-name drug – and their profits – are playing games to stave off generic competitors, leaving patients out in the cold.

Read More

Indian pharma cos get record 300 USFDA generic drug nods in 2017 – Times of India

MUMBAI: Domestic pharma companies received more than 300 approvals in 2017 to launch generic drugs in the US, which is an all-time high. The clearances came despite regulatory pressure from the US Food and Drug Administration ( FDA), and unprecedented warning letters issued to the pharma companies’ facilities.

Read More

Congress can liberate drugs that come off their patents

Brand name drugs are protected by patents, which are government-granted monopolies. Federal enforcement of such patents prohibits anyone else from making or producing the patented product or process during the period the patent is in force. The U.S. Constitution specifically provides for patents, to encourage innovation.

Read More

India fast emerging as inventors’ hub for drugs patent – ET HealthWorld

Chandigarh, Dec 24 (ANI): India is fast emerging as an inventors’ hub for patents for an assortment of drugs worldwide. Around 15 per cent of the total 1.3 lakh patents filed in India from 2013 to 2015 have been contributed by the indigenous pharmaceutical industry.

Read More